Gelonghui November 22|Qiming Medical-B (02500.HK) announced that on November 22, 2023, the company and Hangzhou Dejin Medical Technology Co., Ltd. (“Dejin Medical”) jointly announced on November 22, 2023, that they have reached an exclusive strategic marketing agreement on Dejin Medical's DragonFly transducer mitral valve clip system (“DF”).
The two sides will carry out in-depth commercial cooperation after DF is approved to enter the market. Dejin Medical will make full use of the market and sales network that Keiming Medical has established over many years covering nearly 500 top three hospitals, perfect market access channels, and a sound clinical technical training system to carry out exclusive commercial cooperation. This also marks that after successfully promoting and applying TAVR procedures in China, Keiming Medical also promoted and popularized the mitral valve repair technology of transfemoral venous catheters with higher clinical training requirements and more complicated operation in China. The two sides will join hands and firmly believe that this cooperation will definitely accelerate the development of valvular heart disease diagnosis and treatment in China and lay a solid foundation for building a comprehensive diagnosis and treatment platform for structural heart disease in China in the future.